Pharmafile Logo
Pharmafocus logo
Advanced Search

Lyrica to be made class C drug in Northern Ireland

April 1, 2019
Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin

Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …

News
shutterstock_273326141

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

A Japanese journalist was ordered to pay ¥3.3 million to an anti-vaccine researcher, this week, after a court found her …

News
shutterstock_57369385

England’s antidepressant prescriptions double to 70m in a decade

March 29, 2019
Medical Communications England, UK, antidepressants, anxiety, depression, pharma

Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …

News
28246711066_52e38bc591_z

ABPI calls for temporary export ban in effort to prevent shortages in case of no-deal Brexit

March 29, 2019
Medical Communications ABPI, UK, brexit, drug shortages, export market

The Association of the British Pharmaceutical Industry (ABPI) has called for a temporary ban on exports as a means of …

News
920x920

Sacklers fraudulently transferred funds to dodge litigation, lawsuit says

March 29, 2019
Medical Communications Litigation, New York, OxyContin, Purdue Pharma, Sackelr, opioids

New York state prosecutors have filed a lawsuit against members of the Sackler family, alleging the Purdue Pharma controllers fraudulently …

News
vertex-headquarters

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019
Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …

News

Working Life: Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering

March 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Working Life, feature

Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.How did …

Feature
eye2

J&J’s antihistamine-releasing contact lens shows promise in Phase 3 trials

March 28, 2019
Research and Development J&J, JJ, eye care, pharma

Johnson and Johnson has unveiled new Phase 3 data on its antihistamine-releasing contact lens, showing that the investigational product led …

News

AMR advisor calls for public utility company to tackle AMR

March 28, 2019
Medical Communications, Research and Development AMR, Lord Jim O'Neill, antimicrobial resistance, pharma, public health

Lord Jim O’Neill, an economist and former government advisor on antimicrobial resistance (AMR), has accused the pharmaceutical industry of “spewing …

News

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …

News

Gilead accused of ripping off US taxpayers

March 28, 2019
Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …

News

Japanese court orders public health campaigner to pay ¥3.3 million to anti-vaccine researcher

March 27, 2019
Medical Communications, Research and Development HPV, Japan, anti vaxx, anti-vaccine, public health, vaccines

Dr Riko Muranaka, a researcher and journalist who has campaigned against misinformation surrounding vaccines, has been ordered to pay ¥3.3 …

News
vaccination_2

Measles outbreak spurs New York County to ban all unvaccinated children from public spaces

March 27, 2019
Research and Development New York, US, pharma, vaccination, vaccines

Rockland County, New York State, is taking serious measures to combat its biggest measles outbreak in decades, making the decision …

News
abbvie_0

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019
Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …

News

Children with high adherence to ADHD medication methylphenidate at greater risk of being prescribed antidepressants

March 27, 2019
Research and Development ADHA, mental health, methylphenidate, mph, psychiatric disorders

Children who were treated with methylphenidate-based medications (i.e. Ritalin) for conditions such as ADHD were at significantly greater risk of …

News
novartis_side_building

Novartis’ new MS drug to cost $88,000 a year

March 27, 2019
Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …

News
920x920

Purdue Pharma settle Oklahoma lawsuit for $270 million

March 26, 2019
Research and Development Oklahoma, OxyContin, Purdue Pharma, opioid crisis, oxycodone

OxyContin drugmaker Purdue Pharma has agreed to pay nearly $270 million to the state of Oklahoma, in order to settle …

News
novo_nordisk_flag

Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes

March 26, 2019
Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

News
peanuts02-lg

Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data

March 26, 2019
Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma

Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026